Venous thromboembolism: Current management

Hannah Stevens; Huyen Tran; Harry Gibbs

doi:10.18773/austprescr.2019.039

Venous thromboembolism: Current management

Hannah Stevens, Huyen Tran, Harry Gibbs

Research output: Contribution to journal › Article › Other › peer-review

6 Citations (Scopus)

Abstract

Anticoagulation is indicated in most cases of venous thromboembolism. Monotherapy with rivaroxaban or apixaban is the preferred option for most adults with acute venous thromboembolism. There are no recommended dose reductions for rivaroxaban or apixaban in venous thromboembolism, unlike for atrial fibrillation. The initial duration of anticoagulation is usually three months. Extended treatment with low-dose rivaroxaban or apixaban is effective in preventing recurrence in patients with a continuing increased risk of thromboembolism. Both drugs have low rates of major bleeding.

Original language	English
Pages (from-to)	123-126
Number of pages	4
Journal	Australian Prescriber
Volume	42
Issue number	4
DOIs	https://doi.org/10.18773/austprescr.2019.039
Publication status	Published - Aug 2019

Keywords

Anticoagulants
Apixaban
Rivaroxaban
Venous thromboembolism
Warfarin

Access to Document

10.18773/austprescr.2019.039Licence: CC BY-NC-ND

Cite this

@article{993a26c422f3439e94db964d583051f7,

title = "Venous thromboembolism: Current management",

abstract = "Anticoagulation is indicated in most cases of venous thromboembolism. Monotherapy with rivaroxaban or apixaban is the preferred option for most adults with acute venous thromboembolism. There are no recommended dose reductions for rivaroxaban or apixaban in venous thromboembolism, unlike for atrial fibrillation. The initial duration of anticoagulation is usually three months. Extended treatment with low-dose rivaroxaban or apixaban is effective in preventing recurrence in patients with a continuing increased risk of thromboembolism. Both drugs have low rates of major bleeding.",

keywords = "Anticoagulants, Apixaban, Rivaroxaban, Venous thromboembolism, Warfarin",

author = "Hannah Stevens and Huyen Tran and Harry Gibbs",

year = "2019",

month = aug,

doi = "10.18773/austprescr.2019.039",

language = "English",

volume = "42",

pages = "123--126",

journal = "Australian Prescriber",

issn = "0312-8008",

publisher = "NPS MedicineWise",

number = "4",

}

TY - JOUR

T1 - Venous thromboembolism

T2 - Current management

AU - Stevens, Hannah

AU - Tran, Huyen

AU - Gibbs, Harry

PY - 2019/8

Y1 - 2019/8

N2 - Anticoagulation is indicated in most cases of venous thromboembolism. Monotherapy with rivaroxaban or apixaban is the preferred option for most adults with acute venous thromboembolism. There are no recommended dose reductions for rivaroxaban or apixaban in venous thromboembolism, unlike for atrial fibrillation. The initial duration of anticoagulation is usually three months. Extended treatment with low-dose rivaroxaban or apixaban is effective in preventing recurrence in patients with a continuing increased risk of thromboembolism. Both drugs have low rates of major bleeding.

AB - Anticoagulation is indicated in most cases of venous thromboembolism. Monotherapy with rivaroxaban or apixaban is the preferred option for most adults with acute venous thromboembolism. There are no recommended dose reductions for rivaroxaban or apixaban in venous thromboembolism, unlike for atrial fibrillation. The initial duration of anticoagulation is usually three months. Extended treatment with low-dose rivaroxaban or apixaban is effective in preventing recurrence in patients with a continuing increased risk of thromboembolism. Both drugs have low rates of major bleeding.

KW - Anticoagulants

KW - Apixaban

KW - Rivaroxaban

KW - Venous thromboembolism

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=85070538325&partnerID=8YFLogxK

U2 - 10.18773/austprescr.2019.039

DO - 10.18773/austprescr.2019.039

M3 - Article

C2 - 31427842

AN - SCOPUS:85070538325

SN - 0312-8008

VL - 42

SP - 123

EP - 126

JO - Australian Prescriber

JF - Australian Prescriber

IS - 4

ER -

Venous thromboembolism: Current management

Abstract

Keywords

Access to Document

Other files and links

Cite this